Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

All of the top stock market stories are ready to go in the TipRanks daily wrap-up.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Shares in medtech giant Johnson & Johnson ($JNJ) rose today as it said it would revolutionize cancer treatment following its $3.05 billion acquisit...

M&A News: Johnson & Johnson Stock (JNJ) Perks Up as it Lands $3B “Hold and Kill” Cancer Deal

Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson today and set a price target of $176.00. Miksic covers the Healthcare se...

Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)

Shares in diaper group Kimberly-Clark ($KMB) collapsed 15% today as investors held their nose over its $48.7 billion acquisition of fellow consumer...

M&A: Diaper Maker Kimberly-Clark Leaks 15% After $48.7B Purchase of Tylenol Maker Kenvue

Insiders have been trading these 5 stocks: (($MU)), (($JNJ)), (($COST)), (($ORCL)) and (($MSTR)). Here is a breakdown of their recent trades and th...

Current Quarter	$2.53	Next Quarter	$2.75
Current Year	$10.87	Next Year	$11.48
QoQ Growth	+8.7%	YoY Growth	+5.6%
3Y EPS CAGR	-9.7%	Target Price	$203.50
Consensus	Buy	Upside	-0.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$203.90	+0.41%	13.19M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$203.90	+0.4%	13.19M
3
4
5
6

JNJ

JNJ

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel